Anna Ah-San Tang

Dr. Anna Ah-San Tang

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2017 in eLife
Verified
Journal Article
Open access
CTChristian Tiede
Christian Tiede
RBRobert Bedford
Robert Bedford
SHSophie J Heseltine
Sophie J Heseltine
GSGina Smith
Gina Smith
IWImeshi Wijetunga
Imeshi Wijetunga
DTDarren Charles Tomlinson
Darren Charles Tomlinson
Molecular recognition reagents are key tools for understanding biological processes and are used universally by scientists to study protein expression, localisation and interactions. Antibodies remain the most widely used of such reagents and many show excellent performance, although some are poorly characterised or have stability or batch variability issues, supporting the use of alternative binding proteins as complementary reagents for many applications. Here we report on the use of Affimer proteins as research reagents. We selected 12 diverse molecular targets for Affimer selection to exemplify their use in common molecular and cellular applications including the (a) selection against various target molecules; (b) modulation of protein function in vitro and in vivo; (c) labelling of tumour antigens in mouse models; and (d) use in affinity fluorescence and super-resolution microscopy. This work shows that Affimer proteins, as is the case for other alternative binding scaffolds, represent complementary affinity reagents to antibodies for various molecular and cell biology applications.

25 March 2014 in Protein Engineering, Design and Selection
Verified
Journal Article
Open access
PDF file
CTChristian Tiede
Christian Tiede
ATAnna Ah-San Tang
Anna Ah-San Tang
SDSarah E. Deacon
Sarah E. Deacon
UMUpasana Mandal
Upasana Mandal
JNJoanne E. Nettleship
Joanne E. Nettleship
MMMichael McPherson
Michael McPherson
We have designed a novel non-antibody scaffold protein, termed Adhiron, based on a phytocystatin consensus sequence. The Adhiron scaffold shows high thermal stability (Tm ca. 101°C), and is expressed well in Escherichia coli. We have determined the X-ray crystal structure of the Adhiron scaffold to 1.75 Å resolution revealing a compact cystatin-like fold. We have constructed a phage-display library in this scaffold by insertion of two variable peptide regions. The library is of high quality and complexity comprising 1.3 × 1010 clones. To demonstrate library efficacy, we screened against the yeast Small Ubiquitin-like Modifier (SUMO). In selected clones, variable region 1 often contained sequences homologous to the known SUMO interactive motif (V/I-X-V/I-V/I). Four Adhirons were further characterised and displayed low nanomolar affinities and high specificity for yeast SUMO with essentially no cross-reactivity to human SUMO protein isoforms. We have identified binders against >100 target molecules to date including as examples, a fibroblast growth factor (FGF1), platelet endothelial cell adhesion molecule (PECAM-1; CD31), the SH2 domain Grb2 and a 12-aa peptide. Adhirons are highly stable and well expressed allowing highly specific binding reagents to be selected for use in molecular recognition applications.

1 June 2016 in Biosensors and Bioelectronics
Verified
Journal Article
Open access
RSR. Sharma
R. Sharma
SDS.E. Deacon
S.E. Deacon
DND. Nowak
D. Nowak
SGS.E. George
S.E. George
MSM.P. Szymonik
M.P. Szymonik
CWC. Wälti
C. Wälti
Biosensors with high sensitivity and short time-to-result that are capable of detecting biomarkers in body fluids such as serum are an important prerequisite for early diagnostics in modern healthcare provision. Here, we report the development of an electrochemical impedance-based sensor for the detection in serum of human interleukin-8 (IL-8), a pro-angiogenic chemokine implicated in a wide range of inflammatory diseases. The sensor employs a small and robust synthetic non-antibody capture protein based on a cystatin scaffold that displays high affinity for human IL-8 with a KD of 35 ± 10 nM and excellent ligand specificity. The change in the phase of the electrochemical impedance from the serum baseline, ∆θ(ƒ), measured at 0.1 Hz, was used as the measure for quantifying IL-8 concentration in the fluid. Optimal sensor signal was observed after 15 min incubation, and the sensor exhibited a linear response versus logarithm of IL-8 concentration from 900 fg/ml to 900 ng/ml. A detection limit of around 90 fg/ml, which is significantly lower than the basal clinical levels of 5-10 pg/ml, was observed. Our results are significant for the development of point-of-care and early diagnostics where high sensitivity and short time-to-results are essential.

30 June 2015 in Chemical Science
Verified
Journal Article
Open access
PDF file
ARAndrea E. Rawlings
Andrea E. Rawlings
JBJonathan P. Bramble
Jonathan P. Bramble
ATAnna Ah-San Tang
Anna Ah-San Tang
LSLori A. Somner
Lori A. Somner
AMAmy E. Monnington
Amy E. Monnington
SSSarah Staniland
Sarah Staniland
Biopanning was used to generate novel artificial binding proteins which are able to control the formation of synthetic cubic nanoparticles of magnetite.

14 November 2017 in Science Signaling
Verified
Journal Article
Open access
PDF file
DHDavid Hughes
David Hughes
CTChristian Tiede
Christian Tiede
NPNatalie Penswick
Natalie Penswick
ATAnna Ah-San Tang
Anna Ah-San Tang
CTChi H. Trinh
Chi H. Trinh
AWAdrian Whitehouse
Adrian Whitehouse
Artificial binding proteins are tools for exploring cellular processes dependent on SUMOylation.

30 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
KHKatarzyna Z. Haza
Katarzyna Z. Haza
HMHeather L. Martin
Heather L. Martin
ARAjinkya Rao
Ajinkya Rao
ATAmy L. Turner
Amy L. Turner
SSSophie E. Saunders
Sophie E. Saunders
DTDarren Charles Tomlinson
Darren Charles Tomlinson
RAS mutations are the most common oncogenic drivers across human cancers, but there remains a paucity of clinically-validated pharmacological inhibitors of RAS, as druggable pockets have proven difficult to identify. Here, we identify two RAS-binding Affimer proteins, K3 and K6, that inhibit nucleotide exchange and downstream signaling pathways with distinct isoform and mutant profiles. Affimer K6 binds in the SI/SII pocket, whilst Affimer K3 is a non-covalent inhibitor of the SII region that reveals a conformer of wild-type RAS with a large, druggable SII/α3 pocket. Competitive NanoBRET between the RAS-binding Affimers and known RAS binding small-molecules demonstrates the potential to use Affimers as tools to identify pharmacophores. This work highlights the potential of using biologics with small interface surfaces to select unseen, druggable conformations in conjunction with pharmacophore identification for hard-to-drug proteins.